548 Odcinki

  1. Late-Stage Trial Underway for Treatment of Rare Obesity Disorder

    Opublikowany: 12.12.2018
  2. RegenxBio Bets Its Gene Therapy Technology Provides Competitive Edge

    Opublikowany: 5.12.2018
  3. The Potential for Digital Health Technologies to Transform Clinical Trials

    Opublikowany: 28.11.2018
  4. Matching Volunteers to Rare Disease Organizations in Need

    Opublikowany: 21.11.2018
  5. How One Rare Disease Organization Used Technology to Provide Greater Patient Insight to FDA

    Opublikowany: 14.11.2018
  6. The Potentially Deadly Consequences of an Oversight in Newborn Screening Tests

    Opublikowany: 7.11.2018
  7. Advancing a New Approach to Sickle Cell Disease

    Opublikowany: 31.10.2018
  8. Conquering Life with a Rare Disease

    Opublikowany: 24.10.2018
  9. Why Rare Disease Drug Developers Need Regular Interaction with the FDA

    Opublikowany: 17.10.2018
  10. Making the Case for an FDA Rare Disease Center of Excellence

    Opublikowany: 10.10.2018
  11. An Elite Runner Makes a Cross-Canada Trek for His Son and Rare Disease

    Opublikowany: 3.10.2018
  12. How Rare Disease Advocates Can Get The Most out of Collaborations

    Opublikowany: 26.09.2018
  13. Establishing Clinical Standards for a Rare Disease

    Opublikowany: 19.09.2018
  14. Teen Rare Disease Advocate Fights the Condition That Took His Brother's Life

    Opublikowany: 12.09.2018
  15. Addressing the Emotional Toll of Rare Diseases

    Opublikowany: 5.09.2018
  16. Forging a Research Agenda for a Rare Disease

    Opublikowany: 29.08.2018
  17. Living with an Uncertain Rare Diagnosis

    Opublikowany: 22.08.2018
  18. A Rare Disease Advocate Teaches Doctors to See and Speak Differently

    Opublikowany: 17.08.2018
  19. The Caregiver Who Cried in the Shower

    Opublikowany: 8.08.2018
  20. Curating Patient Data to Accelerate Rare Disease Drug Development

    Opublikowany: 1.08.2018

18 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site